Inozyme Pharma Announces Dosing of First Patient in First-in-Human Clinical Trial of INZ-701 in Patients with ENPP1 DeficiencyGlobeNewsWire • 11/15/21
Wall Street Analysts Believe Inozyme Pharma, Inc. (INZY) Could Rally 257%: Here's is How to TradeZacks Investment Research • 11/12/21
Inozyme Pharma Announces Presentation of Data from ENPP1 Deficiency Development Program at the ASBMR 2021 Annual MeetingGlobeNewsWire • 10/04/21
Inozyme Pharma to Present at the 2021 Cantor Virtual Global Healthcare ConferenceGlobeNewsWire • 09/22/21
Inozyme Pharma Reports Q2 2021 Financial Results and Provides Business HighlightsGlobeNewsWire • 08/11/21
Inozyme Pharma to Participate in 2021 Wedbush PacGrow Healthcare Virtual ConferenceGlobeNewsWire • 08/04/21
Inozyme Pharma Receives Orphan Drug Designation for INZ-701 from the European Medicines Agency for the Treatment of ABCC6 DeficiencyGlobeNewsWire • 07/21/21
Inozyme Pharma Announces Appointment of Gayle Gironda as Senior Vice President, Human ResourcesGlobeNewsWire • 07/13/21
Inozyme Announces Acceptance of First European Clinical Trial Application for Phase 1/2 Clinical Trial of INZ-701 in ABCC6 DeficiencyGlobeNewsWire • 06/09/21
Inozyme Pharma Reports Q1 2021 Financial Results and Provides Business HighlightsGlobeNewsWire • 05/12/21
Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 DeficiencyGlobeNewsWire • 05/07/21
Inozyme Pharma Publishes Data Supporting INZ-701 as a Potential Treatment for ENPP1 DeficiencyGlobeNewsWire • 04/29/21
Inozyme Pharma and Researchers from Thomas Jefferson University to Present Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency at Two Upcoming Medical ConferencesGlobeNewsWire • 04/28/21
Inozyme Pharma Presents Data from Burden of Illness Study in Patients with ENPP1 Deficiency and ABCC6 Deficiency at the 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and GenomicsGlobeNewsWire • 04/14/21
Inozyme Pharma to Present Burden of Illness Data at the 2021 ACMG Annual Clinical Genetics MeetingGlobeNewsWire • 04/08/21
Inozyme Pharma Reports Full Year 2020 Financial Results and Provides Business HighlightsGlobeNewsWire • 03/25/21
Inozyme Pharma Appoints Deborah Wenkert, M.D., as Senior Vice President and Chief Medical OfficerGlobeNewsWire • 02/04/21
Inozyme Pharma Announces Authorization to Proceed in U.S. and U.K. with Phase 1/2 Clinical Trial of INZ-701 for the Treatment of ENPP1 DeficiencyGlobeNewsWire • 01/04/21
Inozyme Pharma Reports Third Quarter 2020 Financial Results and Provides Business HighlightsGlobeNewsWire • 11/12/20